GON Stock Chart & Stats
CHF1.22
--
Market closed
CHF1.22
--
Day’s Range― - ―
52-Week RangeCHF0.91 - CHF1.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
CHF612.99M
Enterprise ValueCHF807.52M
Total Cash (Recent Filing)CHF300.85M
Total Debt (Recent Filing)CHF122.14M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 04, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF3.57Price Target Upside192.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.04
Revenue Forecast (FY)CHF194.82M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth indicates expanding commercial adoption of RYTELO and supports management’s expectation of reaching the mid- to high-end of 2026 guidance. Continued top-line expansion can improve operating leverage and strengthen the company’s ability to fund its oncology pipeline.
Commercial Account ExpansionA broader prescribing-account base and increasing use in earlier treatment lines expand the product’s commercial reach beyond initial adopters. This supports more durable demand, improves access to eligible patients, and gives future sales growth multiple adoption pathways.
Operating LeverageExpense discipline alongside materially faster revenue growth demonstrates improving operating leverage as commercialization scales. If this relationship persists, incremental sales should contribute more efficiently toward reducing losses and funding clinical development without equivalent cost growth.
Bears Say
Cash Burn And LossesHeavy cash consumption and continuing net losses mean the business is not yet self-funding despite revenue growth. Persistent burn can reduce financial flexibility and may require external financing or balance-sheet resources to sustain commercialization and clinical investment.
Rising Gross-to-Net DeductionsHigher gross-to-net deductions reduce realized revenue per unit and can limit the profitability of expanding product demand. If elevated deductions persist, Geron may need stronger pricing, reimbursement, or commercial execution to convert prescription growth into proportional net sales.
Clinical And Regulatory UncertaintyReassessing the interim-analysis threshold introduces uncertainty around the timing and regulatory path for the myelofibrosis program. Although the base-case final overall-survival analysis remains targeted for H2 2028, evolving trial parameters could affect development planning and future expansion prospects.
Geron News
GON FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was CHF0.91 and its highest was CHF1.30 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is CHF612.99M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 04, 2026 which is in 7 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -CHF0.017 earnings per share for the quarter, missing the consensus estimate of -CHF0.007 by -CHF0.009.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -CHF0.017 in its last earnings report, missing expectations of -CHF0.007. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in CH:GON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF3.57 (192.53% Upside)
CHF3.57 (192.53% Upside)
Blogger Sentiment
Bullish
CH:GON Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.15%
12-Months-Change
Fundamentals
Return on Equity
-30.31%
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all CH:GON earnings summariesGON Stock 12 Month Forecast
Average Price Target
CHF3.57
▲(192.53% Upside)